Corey Michael Watton Sells 12,300 Shares of Zevra Therapeutics (NASDAQ:ZVRA) Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Director Corey Michael Watton sold 12,300 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $11.25, for a total value of $138,375.00. Following the sale, the director owned 1,800 shares in the company, valued at $20,250. The trade was a 87.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Zevra Therapeutics Stock Up 0.9%

ZVRA traded up $0.10 during trading on Wednesday, reaching $11.44. The company had a trading volume of 697,529 shares, compared to its average volume of 1,355,583. The stock has a market cap of $679.35 million, a P/E ratio of 12.43 and a beta of 0.91. The business has a 50 day simple moving average of $12.33 and a 200-day simple moving average of $10.62. Zevra Therapeutics, Inc. has a 52 week low of $7.16 and a 52 week high of $15.03.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.14. Zevra Therapeutics had a net margin of 42.82% and a return on equity of 54.54%. The business had revenue of $39.66 million for the quarter, compared to analysts’ expectations of $33.88 million. As a group, equities research analysts expect that Zevra Therapeutics, Inc. will post 0.6 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ZVRA. AIGH Capital Management LLC purchased a new stake in Zevra Therapeutics in the first quarter worth about $11,184,000. Dimensional Fund Advisors LP grew its holdings in Zevra Therapeutics by 259.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 554,802 shares of the company’s stock worth $5,168,000 after acquiring an additional 400,336 shares in the last quarter. Hennion & Walsh Asset Management Inc. increased its position in Zevra Therapeutics by 116.6% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 383,706 shares of the company’s stock valued at $5,502,000 after purchasing an additional 206,543 shares during the period. UBS Group AG increased its position in Zevra Therapeutics by 30.9% during the 4th quarter. UBS Group AG now owns 285,488 shares of the company’s stock valued at $2,558,000 after purchasing an additional 67,392 shares during the period. Finally, Retirement Planning Co of New England Inc. raised its holdings in shares of Zevra Therapeutics by 10.4% in the 4th quarter. Retirement Planning Co of New England Inc. now owns 662,976 shares of the company’s stock valued at $5,940,000 after purchasing an additional 62,206 shares in the last quarter. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Citizens Jmp upped their price target on shares of Zevra Therapeutics from $25.00 to $28.00 and gave the company a “market outperform” rating in a report on Thursday, August 6th. UBS Group reissued a “buy” rating on shares of Zevra Therapeutics in a research note on Wednesday, June 24th. Canaccord Genuity Group dropped their target price on Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating for the company in a research report on Monday, July 27th. BTIG Research reduced their price target on Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating on the stock in a report on Monday, July 27th. Finally, Cantor Fitzgerald raised their price target on Zevra Therapeutics from $24.00 to $34.00 and gave the stock an “overweight” rating in a research note on Monday, June 8th. Nine equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Zevra Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $27.14.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.